🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Theriva Biologics, Inc. TOVX PHARMA

Healthcare · Biotechnology · United States
https://therivabio.com
Company Profile ↓
$0.25
-43.84% 1Y
Mkt Cap$11.47M
P/E0.17
P/B0.88
52W High$0.84
52W Low$0.18
Book Value$0.27
EPS (TTM)$1.44

Company Overview

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 0.2, below the sector median of 24.8.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.29.

Growth & Price Performance

Stock Price Performance

1 Year:-43.84%
6 Months:+37.28%
3 Months:-4.96%
1 Month:+12.32%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 11% of range
$0.18 $0.84
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)57.28 · Neutral
Price Performance
1M+12.32%
3M-4.96%
6M+37.28%
1Y-43.84%
Valuation vs Sector

P/E of 0.17 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 70.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
0.17
Industry PE
24.83
Forward P/E
-1.25
PEG Ratio
-
Book Value
$0.27
Price to Book
0.88
P/S
35.72
EV/EBITDA
-0.24
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-85.21%
ROE
-101.87%
ROA
-21.34%
Profit Margin
0.00%
Op Margin
-
Gross Margin
100.00%
EPS (Latest Qtr)
$-0.05
EPS (TTM)
$1.44

Balance Sheet & Liquidity

Debt/Equity
0.29
Quick Ratio
1.08
Current Ratio
1.13
Debt
$3.55M
Total Assets
$38.25M
Current Assets
$16.76M
Working Capital
$7.45M

Ownership

Promoter Holding
1.63%
Chg in Prom Hold
-
FII / Inst Holding
4.35%
Chg in FII Hold
-0.04%

Financial Snapshot

Enterprise Value
$11.47M
Total Revenue (TTM)
$300.00K
EBITDA
$-11.96M
Free Cash Flow
$-6.69M
Operating Cash Flow
$-12.74M
Shares Outstanding
45.89M
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TOVX Theriva Biologics, Inc. PHARMA 0.25 0.17 $11.47M 0.00% -85.21% -101.87% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------------------------------0000300.00K
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------4.42M13.13M4.44M2.06M2.43M
Operating Income -8.21M-9.73M-11.65M--10.58M-9.31M-9.16M--8.15M-6.47M-5.84M--4.99M-5.00M-4.32M--3.57M-3.64M-5.24M-3.03M-2.89M-2.11M-2.54M-3.20M-3.27M-4.25M-5.03M-4.99M-5.18M-5.82M-4.22M-5.39M-8.49M-7.89M--4.42M-13.13M-4.44M-2.06M-2.13M
EBITDA ------------------------------------4.39M-13.11M-4.41M-2.04M-2.10M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------4.32M-13.06M-4.36M-2.00M-2.04M
Tax Provision -----------------------------------00000
Net Income -12.36M-13.62M-7.51M-11.30M-11.08M-5.76M-8.49M-2.47M-3.06M-4.32M-10.93M2.81M-2.32M-4.20M-3.68M-3.19M-3.51M-3.53M-5.12M-2.96M-2.87M-2.10M-2.54M-3.19M-3.27M-4.27M-4.48M-4.49M---3.30M-----4.32M-13.06M-4.36M-2.00M-2.04M
Diluted EPS -0.17-0.19-0.12-0.12-0.12-0.10-0.09-0.02-0.70-1.05-4.900.76-0.65-1.16-0.93-1.12-0.25-0.23-0.31---0.14-0.13-0.24-0.25-0.31-0.28-0.30-0.30-0.34-4.85-7.53-10.72-6.81--1.55-1.93-0.45--0.05
R&D Expense 6.49M7.51M10.05M-8.15M7.16M7.06M-6.06M4.83M4.14M-3.37M3.57M2.85M-2.42M2.59M4.14M1.64M1.60M914.00K1.12M1.93M1.97M2.60M3.48M2.57M2.98M3.13M4.01M3.46M2.95M2.73M-2.97M1.95M2.55M-355.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 2.61M0----------0000
Cost of Revenue ----------------
Gross Profit ----------------
Operating Expenses ------------21.58M21.43M19.43M24.05M
Operating Income ---17.30M-12.34M-20.50M-40.98M-39.25M-26.25M-17.57M-15.66M-10.16M--21.58M-21.43M-19.43M-24.05M
EBITDA -------------21.50M-21.30M-19.29M-23.94M
Interest Expense ----------------
Pretax Income -------------21.11M-19.99M-25.65M-23.74M
Tax Provision -------------1.43M-1.64M00
Net Income -1.71M-8.15M-17.07M-12.32M-19.78M-43.74M-27.25M-15.17M-13.37M-15.30M-10.04M--19.68M-18.35M-25.65M-23.74M
Diluted EPS -----------0.66--32.75-28.48-19.03-2.08
R&D Expense 1.58M3.34M12.29M6.51M14.49M32.91M29.11M18.78M11.84M11.08M5.13M7.80M11.72M14.31M12.03M8.60M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Feb 2019Sep 2019Dec 2019Dec 2020Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -4.11M7.48M13.42M16.26M19.14M30.84M22.50M18.84M30.14M--17.23M8.41M--80.64M77.11M71.86M55.22M35.35M38.24M
Current Assets ------------------45.52M27.40M16.28M17.47M
Cash & Equivalents --6.68M9.95M14.62M17.52M20.82M19.05M17.12M28.92M26.00M-15.04M6.23M--52.27M50.49M41.79M23.18M11.61M13.06M
Inventory ----------------------
Receivables ------------------231.00K1.94M3.32M3.83M
Total Liabilities -532.00K417.00K395.00K1.03M9.59M15.84M20.25M10.20M3.69M--5.75M3.15M--18.42M17.99M17.30M15.52M16.29M22.86M
Current Liabilities -500.00K417.00K395.00K1.03M9.59M15.57M19.76M9.79M3.38M--5.28M2.97M--12.42M12.32M7.06M6.74M7.58M10.01M
Long Term Debt ------------------221.00K162.00K92.00K1.67M
Total Debt ------------------1.68M2.15M1.56M2.63M
Total Equity 3.54M3.58M7.06M13.03M15.23M9.56M16.05M3.85M-1.50M17.07M-4.93M1.82M-4.77M-68.03M62.22M56.39M54.56M39.70M19.07M15.38M
Shares Outstanding ------------------633.76K714.73K2.81M35.72M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --1.15M-2.88M-8.92M-7.72M-16.08M-38.89M-27.90M-20.20M-17.28M-13.87M-12.17M--19.08M-19.00M-16.94M-16.67M
Investing Cash Flow -65.00K-75.00K-10.00K-36.00K-48.00K-501.00K-569.00K-212.00K-7.00K0-9.00K--4.40M-202.00K-1.00K-35.00K
Financing Cash Flow -1.01M6.98M12.20M12.43M19.03M42.68M26.71M18.48M29.09M03.36M--1.93M625.00K5.50M18.19M
Capital Expenditure --12.00K-0-10.00K-36.00K-48.00K-501.00K-569.00K-212.00K-7.00K-0-9.00K--116.00K-202.00K-1.00K-35.00K
Free Cash Flow --1.16M-2.88M-8.93M-7.75M-16.13M-39.39M-28.47M-20.42M-17.29M-13.87M-12.18M--19.20M-19.20M-16.94M-16.70M
Net Change in Cash --------------25.41M-18.57M-11.44M1.49M
Share Buybacks 1.00M----------------

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------------
Operating Margin % ----------------
Net Margin % -65.5%---------------
ROE % -47.8%-115.4%-131.0%-80.9%-207.0%-272.5%-708.8%1,014.3%-78.3%-840.4%210.7%--36.1%-46.2%-134.5%-154.3%
ROCE % ---132.8%-81.0%-214.5%-268.4%-1,432.0%-290.2%-65.7%-131.0%-186.6%--33.3%-44.2%-70.0%-85.2%

Shareholding Pattern

Insiders
1.63%
Institutions
4.35%
Public Float
4.42%

Top Institutional Holders

#Holder% HeldSharesValue
1 Vanguard Capital Management LLC 1.06% 486.18K $113.52K
2 Jane Street Group, LLC 0.72% 331.92K $77.50K
3 Geode Capital Management, LLC 0.64% 294.02K $68.65K
4 Vanguard Fiduciary Trust Co 0.53% 241.78K $56.45K
5 Ikarian Capital, LLC 0.24% 112.08K $26.17K
6 Virtu Financial LLC 0.19% 87.14K $20.35K
7 Northern Trust Corporation 0.18% 82.70K $19.31K
8 Renaissance Technologies, LLC 0.14% 63.71K $14.88K
9 UBS Group AG 0.13% 61.05K $14.26K
10 Xtx Topco Ltd 0.12% 53.87K $12.58K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TOVX

Google News Sat, 29 Aug 2026

TOVX Should I Buy - Intellectia AI

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1wTFlXY3p4Z2VDbzJPTzBaMU1EQjFSaEl1ZUpEaWRid25iSFBidlFIX1BFMUlnU2xCWkJsdTBoOWZhdVFydlBtTlg2T29kMEtsbFZfNWVFN1ZNZjFXU0E?oc=5" target="_blank">TOVX Should I Buy</a>&nbsp;&nbsp;<font c…

Google News Fri, 26 Jun 2026

TOVX Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFA4alpYdno5bTJjRnZSUEU1R1ZMSkowM2hoU1JIdzIyamZVZE1fT0d1NmRHVkRxT0FFTWJXaFJfckFCekR5S0ZZOHpWZHZ6Qzc3ZkpRTlhDYnNUaUNtSXJkZm1Dc24ta1lpQmhXSE8xU3NBaDZhU0ZV?oc=5" target="_blank">TOVX Fo…

Google News hu, 11 Jun 2026

Small trial: virus-immunotherapy combo linked to longer survival in head and neck cancer - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNaVRQczFyWFplUDJUMmFsVTJORERrdmNqdlZjc2VQbWtwVGNKdlJ5TWY1MDQ3WHdub0dFSTNYYVVZaGRwOVJiVGU1MGMxRld4ZUlZeWRJUEdHY2VEY3pWZDJjcGZ6bW4tUVZXVm0zR3NsU2lXMTlBSGtZdzZfQmxOR2NfU3A0dDB6NVFVcV…

Google News hu, 28 May 2026

TOVX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBnZGp1Y1lfdkZWbmxTMDVPSzJqNzJfTkhjdjU5R2ljaXY2eGYxeVJQSUt3akV0cW1tRzdzQVdncWhZcW05ZVE?oc=5" target="_blank">TOVX</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News ue, 11 Aug 2026

Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress | TOVX Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOX1gxTy0zSEJvRWNockludGx6NURlYWZ1YlljVzlyR3pmUWtQT09NRzBUWURNbjlncGNEb0d6a0dBQkdwZFZoV285TnlQUFp5dkR3NFBvNy1Hem1KYkxTVW1DSmpWRmZNa2FxakljdUtURDZVTnhITHpqU1VnRXZXaEJGTmZBR2lzVUFJcz…

Google News hu, 05 Mar 2026

What’s Getting Investors So Excited About TOVX Stock? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQNnA4OUQ4Y0hOeUpYN0VnMlBReUcwTVVOSW9BV0ktSlYwdHFTYjh1TDI1MG8zc0pDdUpXSFRlc3hwaGRydlUyenVKcUFCUnBTeTBJUFZmXzFLOWxzVFZqZTZ1V1JGVk5nSGtDM2gtSTNlT2lMUEcwWGUzWmF2RjdEZ1pENFJVUUowNTl3Yn…

TOVX — Frequently Asked Questions

What is the current share price of Theriva Biologics, Inc. (TOVX)?

As of 2026-09-19 21:16 PDT, Theriva Biologics, Inc. (TOVX) trades at $0.25 on NYSE American. Its 52-week range is $0.18 to $0.84.

What is the market capitalisation of TOVX?

Theriva Biologics, Inc. (TOVX) has a market capitalisation of $11.47M on NYSE American.

What is the P/E ratio of TOVX?

TOVX trades at a trailing price-to-earnings (P/E) ratio of 0.17. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.88.

What is the return on equity (ROE) of TOVX?

TOVX has a return on equity (ROE) of -101.87%. Its return on capital employed (ROCE) is -85.21%.

Is TOVX a good stock to buy?

This page provides a data-driven analysis of Theriva Biologics, Inc. (TOVX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space